Global Alpha Emitters Market - Growth, Trends and Forecasts (2015 - 2020)

Nov 02, 2015, 17:07 ET from ReportBuyer

LONDON, Nov. 2, 2015 /PRNewswire/ -- The global market for alpha emitters is currently estimated to be valued at $XX million for the year 2015 and is poised to reach $XX million by the end of 2020. The CAGR during this period of forecast is XX%.

Alpha emitter radionuclide is considered to be a new approach to tackle cancer and related issues. Alpha emitter provides many advantages when compared to beta emitters and photon therapy, making it an increasingly preferred mode of treatment. As a result, this has caught the attention of major players interested in capitalizing the market potential.

Alpha emitters are currently used in the process of Targeted Alpha Therapy (TAT), where in an alpha emitter radionuclide exposes a certain amount of radiation dose to tumor cells, at a very early stage or in the state of metastasis, and destroy the respective cancer cells. In contrast to chemotherapy, TAT allows easy discrimination between the healthy cells and cancer cells. This is helpful in reducing the side effects associated with Chemotherapy.

The number of therapeutic procedures recorded in North America, Europe and Asia-Pacific are 265, 22195, and 271248 respectively for the year 2013. Country-wise, US have 262 therapeutic procedures. Developing countries like India hold strong market potential, accounting for 7475 therapeutic procedures.

The global market for alpha emitters can be segmented on the basis of radionuclide used (Terbium, Astatine, Bismuth, Actinium, Radium, Lead, Bismuth (Bi-213) and Others), type of medical application (Endocrine tumors, Lymphoma, Bone metastasis, Glioma, Melanoma, Pancreatic Cancer, Ovarian Cancer, Thyroid and Others), on the basis of Geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa).


Major drivers contributing to growth of the market are increasing incidences of cardiac & cancer ailments, increased awareness about the potential benefits of targeted alpha therapy and increasing availability of radiopharmaceuticals.


Shorter life of radiopharmaceuticals, need for high capital investment, stringent regulatory framework and reimbursement issues are the major factors impacting market growth.

What the report offers

Market definition for the specified topic along with identification of key drivers and restraints for the market
Market analysis of the global alpha emitters market, with region specific assessments and competition analysis
Identification of factors instrumental in changing the market scenarios, offering prospective opportunities and the identification of key companies, which can influence the market on the global and regional scales
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares
Identification and analysis of the macro and micro factors that affect the global alpha emitters market on both the global and regional fronts
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information
Download the full report:

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at
Tel: +44 208 816 85 48

SOURCE ReportBuyer